Cargando…
Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs
Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic inflammation and is mediated by multiple immune cell types. In this work, we aimed to determine the relevance of changes in cell proportions in peripheral blood mononuclear cells (PBMCs) during the development of disease an...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284888/ https://www.ncbi.nlm.nih.gov/pubmed/37344505 http://dx.doi.org/10.1038/s41598-023-36999-0 |
_version_ | 1785061491196559360 |
---|---|
author | Hedman, Åsa K. Winter, Eitan Yoosuf, Niyaz Benita, Yair Berg, Louise Brynedal, Boel Folkersen, Lasse Klareskog, Lars Maciejewski, Mateusz Sirota-Madi, Alexandra Spector, Yael Ziemek, Daniel Padyukov, Leonid Shen-Orr, Shai S. Jelinsky, Scott A. |
author_facet | Hedman, Åsa K. Winter, Eitan Yoosuf, Niyaz Benita, Yair Berg, Louise Brynedal, Boel Folkersen, Lasse Klareskog, Lars Maciejewski, Mateusz Sirota-Madi, Alexandra Spector, Yael Ziemek, Daniel Padyukov, Leonid Shen-Orr, Shai S. Jelinsky, Scott A. |
author_sort | Hedman, Åsa K. |
collection | PubMed |
description | Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic inflammation and is mediated by multiple immune cell types. In this work, we aimed to determine the relevance of changes in cell proportions in peripheral blood mononuclear cells (PBMCs) during the development of disease and following treatment. Samples from healthy blood donors, newly diagnosed RA patients, and established RA patients that had an inadequate response to MTX and were about to start tumor necrosis factor inhibitors (TNFi) treatment were collected before and after 3 months of treatment. We used in parallel a computational deconvolution approach based on RNA expression and flow cytometry to determine the relative cell-type frequencies. Cell-type frequencies from deconvolution of gene expression indicate that monocytes (both classical and non-classical) and CD4(+) cells (T(h)1 and T(h)2) were increased in RA patients compared to controls, while NK cells and B cells (naïve and mature) were significantly decreased in RA patients. Treatment with MTX caused a decrease in B cells (memory and plasma cell), and a decrease in CD4 T(h) cells (T(h)1 and T(h)17), while treatment with TNFi resulted in a significant increase in the population of B cells. Characterization of the RNA expression patterns found that most of the differentially expressed genes in RA subjects after treatment can be explained by changes in cell frequencies (98% and 74% respectively for MTX and TNFi). |
format | Online Article Text |
id | pubmed-10284888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102848882023-06-23 Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs Hedman, Åsa K. Winter, Eitan Yoosuf, Niyaz Benita, Yair Berg, Louise Brynedal, Boel Folkersen, Lasse Klareskog, Lars Maciejewski, Mateusz Sirota-Madi, Alexandra Spector, Yael Ziemek, Daniel Padyukov, Leonid Shen-Orr, Shai S. Jelinsky, Scott A. Sci Rep Article Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic inflammation and is mediated by multiple immune cell types. In this work, we aimed to determine the relevance of changes in cell proportions in peripheral blood mononuclear cells (PBMCs) during the development of disease and following treatment. Samples from healthy blood donors, newly diagnosed RA patients, and established RA patients that had an inadequate response to MTX and were about to start tumor necrosis factor inhibitors (TNFi) treatment were collected before and after 3 months of treatment. We used in parallel a computational deconvolution approach based on RNA expression and flow cytometry to determine the relative cell-type frequencies. Cell-type frequencies from deconvolution of gene expression indicate that monocytes (both classical and non-classical) and CD4(+) cells (T(h)1 and T(h)2) were increased in RA patients compared to controls, while NK cells and B cells (naïve and mature) were significantly decreased in RA patients. Treatment with MTX caused a decrease in B cells (memory and plasma cell), and a decrease in CD4 T(h) cells (T(h)1 and T(h)17), while treatment with TNFi resulted in a significant increase in the population of B cells. Characterization of the RNA expression patterns found that most of the differentially expressed genes in RA subjects after treatment can be explained by changes in cell frequencies (98% and 74% respectively for MTX and TNFi). Nature Publishing Group UK 2023-06-21 /pmc/articles/PMC10284888/ /pubmed/37344505 http://dx.doi.org/10.1038/s41598-023-36999-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Hedman, Åsa K. Winter, Eitan Yoosuf, Niyaz Benita, Yair Berg, Louise Brynedal, Boel Folkersen, Lasse Klareskog, Lars Maciejewski, Mateusz Sirota-Madi, Alexandra Spector, Yael Ziemek, Daniel Padyukov, Leonid Shen-Orr, Shai S. Jelinsky, Scott A. Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs |
title | Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs |
title_full | Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs |
title_fullStr | Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs |
title_full_unstemmed | Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs |
title_short | Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs |
title_sort | peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284888/ https://www.ncbi.nlm.nih.gov/pubmed/37344505 http://dx.doi.org/10.1038/s41598-023-36999-0 |
work_keys_str_mv | AT hedmanasak peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT wintereitan peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT yoosufniyaz peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT benitayair peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT berglouise peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT brynedalboel peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT folkersenlasse peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT klareskoglars peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT maciejewskimateusz peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT sirotamadialexandra peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT spectoryael peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT ziemekdaniel peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT padyukovleonid peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT shenorrshais peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs AT jelinskyscotta peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs |